Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

First-Line T-DXd Combinations Show Early Antitumor Activity in HER2+ Gastric/GEJ Cancers

September 14th 2024

First-line combinations with trastuzumab deruxtecan showed initial efficacy in HER2-positive esophageal, gastric, and gastroesophageal junction cancers.

IMM-1-104 and Chemo Combination Elicit Responses in First-Line Pancreatic Cancer

September 13th 2024

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

September 11th 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma

September 5th 2024

ABD-147 has received orphan drug designation from the FDA for use in patients with neuroendocrine carcinoma.

FDA Grants Orphan Drug Designation to Certepetide in Cholangiocarcinoma

September 5th 2024

Certepetide has been granted orphan drug designation by the FDA for the treatment of patients with cholangiocarcinoma.

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma

August 31st 2024

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

August 30th 2024

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

Dr Liao on the Value of Molecular Testing in Biliary Tract Carcinoma

August 28th 2024

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Dr El-Khoueiry on Immune Suppression in Advanced HCC After Checkpoint Inhibitors

August 27th 2024

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Dr Devoe on Next Steps for Evaluating ELI-002 7P in MRD+ KRAS-Mutant PDAC and CRC

August 26th 2024

Craig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.

Dr Kelly on Ongoing Trials in Patients With GIST

August 26th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

Dr Kelly on the Evaluation of the Combination of Ripretinib and DCC-3116 in GIST

August 23rd 2024

Ciara Kelly, MBBCh, BAO, discusses the evaluation of DCC-3116 in combination with ripretinib in advanced gastrointestinal stromal tumor.

FDA Accepts sBLA for First-Line Nivolumab Plus Ipilimumab in Unresectable HCC

August 21st 2024

The FDA has accepted a supplemental biologics license application for nivolumab plus ipilimumab for first-line unresectable hepatocellular carcinoma.

Dr Kelly on the Importance of Testing For Genetic Abnormalities in GIST

August 21st 2024

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

FDA Awards Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma

August 19th 2024

The FDA has granted orphan drug designation to PT217 for the treatment of patients with neuroendocrine carcinoma.

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

August 19th 2024

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

Analyzing the “RAS Pie” for Methods to Target Mutations in GI Cancers

August 14th 2024

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

T-DXd Wins Conditional Approval in China for Pretreated HER2+ Gastric/GEJ Cancer

August 13th 2024

Trastuzumab deruxtecan earned conditional approval in China for HER2-positive gastric/gastroesophageal junction cancer after at least 2 lines of therapy.

Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.